Finally, in chronic myeloid leukemia (CML), it is well known that patients respond well to tyrosine kinase inhibitors (TKIs) of the BCR-ABL oncoprotein, without eradicating the disease due to rare TKIs insensitive LICs. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.